Tamoxifen
Breast Cancer
ApprovedCommercial
Key Facts
About Natco Pharma
Natco Pharma Limited is a vertically integrated pharmaceutical company with a mission to improve patient access to high-quality, affordable medicines. The company has established itself as a leader in the Indian generics market, with significant achievements in developing and commercializing complex generics, including oncology drugs like lenalidomide and hepatitis C treatments. Its strategic direction focuses on expanding its branded generics portfolio, strengthening its API business, and pursuing growth in regulated markets like the US through its subsidiary Natco Pharma USA.
View full company profileTherapeutic Areas
Other Breast Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Verzenio (abemaciclib) | Eli Lilly | Approved |
| Pan-mutant-selective PI3Kα inhibitor | Novartis | Acquisition |
| Trodelvy | Royalty Pharma | Commercial |
| Trastuzumab biosimilar (IBI306) | Innovent Biologics | Phase 3 |
| Ogivri (trastuzumab biosimilar) | Viatris | Approved |
| Trastuzumab Biosimilar | Dr. Reddy's Laboratories | Approved |
| Biosimilar Trastuzumab | Cipla | Commercial |
| Ogivri (Trastuzumab) | Biocon | Approved |
| ARV-027 | Arvinas | Phase 1 |
| Prognostic Genomic Tests | Eurobio Scientific | Commercial |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| ATNM-400 | Actinium Pharmaceuticals | Preclinical |